175 related articles for article (PubMed ID: 14613121)
1. Rapid diversity-oriented synthesis in microtiter plates for in situ screening of HIV protease inhibitors.
Brik A; Muldoon J; Lin YC; Elder JH; Goodsell DS; Olson AJ; Fokin VV; Sharpless KB; Wong CH
Chembiochem; 2003 Nov; 4(11):1246-8. PubMed ID: 14613121
[No Abstract] [Full Text] [Related]
2. Development of low molecular weight HIV-1 protease dimerization inhibitors.
Hwang YS; Chmielewski J
J Med Chem; 2005 Mar; 48(6):2239-42. PubMed ID: 15771466
[TBL] [Abstract][Full Text] [Related]
3. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
Sperka T; Pitlik J; Bagossi P; Tözsér J
Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
[TBL] [Abstract][Full Text] [Related]
4. Rapid synthesis and in situ screening of potent HIV-1 protease dimerization inhibitors.
Lee SG; Chmielewski J
Chem Biol; 2006 Apr; 13(4):421-6. PubMed ID: 16632254
[TBL] [Abstract][Full Text] [Related]
5. Rapid discovery and structure-activity profiling of novel inhibitors of human immunodeficiency virus type 1 protease enabled by the copper(I)-catalyzed synthesis of 1,2,3-triazoles and their further functionalization.
Whiting M; Tripp JC; Lin YC; Lindstrom W; Olson AJ; Elder JH; Sharpless KB; Fokin VV
J Med Chem; 2006 Dec; 49(26):7697-710. PubMed ID: 17181152
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial design of nonsymmetrical cyclic urea inhibitors of aspartic protease of HIV-1.
Frecer V; Burello E; Miertus S
Bioorg Med Chem; 2005 Sep; 13(18):5492-501. PubMed ID: 16054372
[TBL] [Abstract][Full Text] [Related]
8. 1,2,3-triazole as a peptide surrogate in the rapid synthesis of HIV-1 protease inhibitors.
Brik A; Alexandratos J; Lin YC; Elder JH; Olson AJ; Wlodawer A; Goodsell DS; Wong CH
Chembiochem; 2005 Jul; 6(7):1167-9. PubMed ID: 15934050
[No Abstract] [Full Text] [Related]
9. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
10. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
[TBL] [Abstract][Full Text] [Related]
11. Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases.
Shi H; Liu K; Leong WW; Yao SQ
Bioorg Med Chem Lett; 2009 Jul; 19(14):3945-8. PubMed ID: 19328682
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
Raza A; Sham YY; Vince R
Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
Narendra Babu SN; Rangappa KS
Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
[TBL] [Abstract][Full Text] [Related]
14. Inorganic polyhedral metallacarborane inhibitors of HIV protease: a new approach to overcoming antiviral resistance.
Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezácová P; Brynda J; Pokorná J; Plesek J; Grüner B; Grantz Sasková K; Václavíková J; Král V; Konvalinka J
J Med Chem; 2008 Aug; 51(15):4839-43. PubMed ID: 18598016
[TBL] [Abstract][Full Text] [Related]
15. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
[TBL] [Abstract][Full Text] [Related]
17. Epoxide opening in water and screening in situ for rapid discovery of enzyme inhibitors in microtiter plates.
Liang FS; Brik A; Lin YC; Elder JH; Wong CH
Bioorg Med Chem; 2006 Feb; 14(4):1058-62. PubMed ID: 16275107
[TBL] [Abstract][Full Text] [Related]
18. High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
Wannberg J; Kaiser NF; Vrang L; Samuelsson B; Larhed M; Hallberg A
J Comb Chem; 2005; 7(4):611-7. PubMed ID: 16004505
[TBL] [Abstract][Full Text] [Related]
19. Revealing interaction mode between HIV-1 protease and mannitol analog inhibitor.
Yan GW; Chen Y; Li Y; Chen HF
Chem Biol Drug Des; 2012 Jun; 79(6):916-25. PubMed ID: 22296911
[TBL] [Abstract][Full Text] [Related]
20. Predicting drug-resistant mutations of HIV protease.
Ishikita H; Warshel A
Angew Chem Int Ed Engl; 2008; 47(4):697-700. PubMed ID: 18058968
[No Abstract] [Full Text] [Related]
[Next] [New Search]